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Abstract
Introduction Neuroleptic malignant syndrome (NMS) is a rare,
but sometimes fatal, adverse reaction to neuroleptics
characterized principally by fever and rigor. The aim of this study
was to prove the efficacy of different NMS treatment strategies,
focusing on the efficacy of dantrolene.
Methods Altogether, 271 case reports were included. These
cases were categorized into four treatment groups and
compared to each other according to effectiveness of therapy
within 24 hours, mortality, complete time of remission in days,
effectiveness due to increase of dosage, relapse on the basis of
decrease of dosage, and improvement of symptoms.
Results Between the four treatment groups, the complete time
of remission was significantly different (analysis of variance, F =
4.02; degrees of freedom = 3; p  = 0.008). In a logistic
regression with adjustment for age, gender, and severity code,
no significant predictor of the treatment for the complete time of
remission (dichotomized by median) could be found. However,
if the premedication was a monotherapy with neuroleptics, the
complete time of remission was significantly shorter with
dantrolene monotherapy (t = -2.97; p = 0.004).
Conclusion The treatment of NMS with drugs that are
combined with dantrolene is associated with a prolongation of
clinical recovery. Furthermore, treatment of NMS with
dantrolene as monotherapy seems to be associated with a
higher overall mortality. Therefore, dantrolene does not seem to
be the evidence-based treatment of choice in cases of NMS but
might be useful if premedication consisted of a neuroleptic
monotherapy.
Introduction
Neuroleptic malignant syndrome (NMS) is a rare, but some-
times fatal, adverse reaction to neuroleptics. It is characterized
principally by fever and muscle rigidity. Furthermore, signs
such as altered consciousness, autonomic instability, and lab-
oratory findings such as elevated creatine phosphokinase
(CPK), leukocytosis, raised liver enzymes, and low serum iron
or potassium levels are also found (serum iron and potassium
levels differ in the sets of diagnostic criteria according to sev-
eral authors [1,2]). NMS is observed mainly in patients treated
with neuroleptics, especially with high-potency neuroleptics,
atypical neuroleptics, low-potency D2-receptor antagonists
such as metoclopramide and tricyclic antidepressants, or after
withdrawal of antiparkinsonians. Because clinical NMS stud-
ies have been conducted mainly in psychiatric units, it has
been suggested that special attention to cancer patients
undergoing psychopharmacologic treatment is necessary
even in oncologic practice [3].
Although the origin of NMS remains unknown, a reduction in
dopaminergic activity in the brain, probably by dopamine D2-
receptor blockade in the striatum and hypothalamus, is gener-
ally assumed as its cause [4,5]. Nevertheless, other theories
about its pathophysiology have been raised, including a distur-
bance of glutamate [6] or serotonin [7,8] receptors, central
hyponatremia [9], overreaction of the sympathetic nerve sys-
tem [8,10], as well as a kind of acute-phase reaction [11].
However, these theories are able to explain neither the
ANOVA = analysis of variance; CI = confidence interval; CPK = creatine phosphokinase; df = degrees of freedom; NMS = neuroleptic malignant 
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symptoms mentioned above nor the low incidence rate
between less than 0.1% and 2.5% of all patients treated with
neuroleptic medication [12].
Therefore, a therapeutic approach inevitably seems to be
through trial rather than evidence-based. It is generally agreed
that it is of highest importance to identify the syndrome, sud-
denly withdraw the offending agent, and entertain supportive
therapy as rehydration and restoring electrolyte balance.
Because anticholinergics anticipate diaphoresis [11], they
should be avoided. In regard to special treatment, several ther-
apeutic options have been established. In addition to bromoc-
riptine and other dopamine D2-receptor agonists, dantrolene
sodium has been recommended predominantly in the past.
Dantrolene is a peripheral muscle relaxant, which inhibits the
intracellular calcium release from the sarcoplasmatic reticu-
lum. It was originally applied to treat cases of malignant hyper-
thermia. It was first mentioned in 1981 as a treatment of NMS
[12] and since then has been employed with more or less suc-
cess. Nevertheless, dantrolene therapy is still considered the
treatment of first choice in current pharmacologic and psychi-
atric textbooks as well as in recent publications [4,13]. Some
authors have suggested a positive central effect of dantrolene
in cases of NMS [14,15]. Since the mid-1980s, the benefit of
specific treatment with dantrolene has been controversial [1].
No significant benefit or even a shortened course of recovery
from NMS through single dantrolene therapy, compared to
supportive therapy alone, could be observed [13,16]. In fact,
failures of dantrolene therapy have been documented in sev-
eral case reports [17-19]. as well as in relatively large samples
[2].
Taking into account the low incidence rate of NMS, a rand-
omized, controlled, and double-blinded prospective study did
not seem to be feasible. Therefore, the aim of this study was
to prove the efficacy of dantrolene therapy by a review of pub-
lished cases and a complete review of the literature.
Materials and methods
For facility of data recall, databases such as PubMed were
searched to obtain a list of more than 600 publications from
the years 1968 to 2006. Inclusion criteria for our study were
the mention of therapy, treatment, dantrolene, case report,
review of literature, and NMS since 1980 in title or abstract.
Exclusion criteria were the exclusive mention of risk factors,
pathophysiology, incidences and biochemistry, differential
diagnosis, or foreign-language articles except those in Ger-
man or English.
Altogether, 271 case reports including information on age,
gender, diagnosis, and some data on therapy could be
extracted. To avoid biases by multiply recorded case reports,
case series were excluded as well. Information was registered
as follows: year of publication, gender, age, diagnosis, trigger-
ing medications for NMS, dosages, time of incidence of NMS,
fever, diaphoresis, pulse, rigidity, 'others' (blood pressure,
level of consciousness, urinary retention, and so on), CPK, leu-
kocytosis, other laboratory parameters (electrolytes, result of a
lumbar puncture, and so on), time of withdrawal of the offend-
ing agent, dantrolene therapy (including dosage), adjuvant
treatments such as cooling or others, course of illness, and
time until complete recovery or death.
Because the main focus of the present study was to evaluate
the efficacy of dantrolene and other treatments of NMS, cases
were divided according to their received therapy into four
treatment groups (Figure 1). The severity of NMS was
assessed according to the Levenson criteria [1,4]. Thereby, it
was possible to establish a comparable baseline status of
patients within the aforementioned treatment groups.
Afterward, six categories pertaining to efficacy of treatment of
NMS were assessed as follows: effectiveness of therapy
within 24 hours, mortality, complete time of remission in days,
effectiveness due to increase of dosage, relapse on the basis
of decrease of dosage, and improvement of symptoms.
Statistical methods
The complete time of remission was transformed by calculat-
ing the natural logarithm. To control for possible confounders,
logistic models were performed in a second step. These mod-
els for the variables were adjusted for age, gender, and fever
as a proxy measure for the severity of the NMS at baseline.
Additionally, χ2 tests and parametric (t tests, analysis of vari-
ance [ANOVA]) and nonparametric (Kruskal-Wallis) tests (in
cases in which distribution was not normal and transformation
was not reasonable) were calculated. The normal distribution
of data was evaluated by the Kolmogorov-Smirnov test. All sta-
tistical tests were two-sided, and significance level was set at
α = 0.05 or less. Data were analyzed using SPSS™ for Win-
dows 11.0.1 (SPSS Inc., Chicago, IL, USA).
Results
In summary, 271 case reports from 27 years (from 1980 to
2006) were included. Only 33.9% of the subjects included
were female. The mean age of patients at the onset of NMS
was 40.4 years (standard deviation 19.3). There was no signif-
icant difference in age between female and male patients (t =
-0.87, p = 0.386).
Figure 1 shows the relative frequency of NMS treatment regi-
mens in the present analysis.
The main criteria regarding effectiveness of therapy such as
effectiveness of therapy within 24 hours, mortality, complete
time of remission in days, effectiveness due to increase of dos-
age, relapse on the basis of decrease of dosage, and improve-
ment of symptoms are displayed in Tables 1 and 2.Available online http://ccforum.com/content/11/1/R4
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Between treatment groups, significant differences in the effec-
tiveness within 24 hours could be observed (χ2 test: χ2 = 16.0;
degrees of freedom [df] = 3; p = 0.001). Interestingly, the
short effectiveness of the dantrolene monotherapy was quite
similar to other kinds of treatment, including bromocriptine,
amantadine, or electroconvulsive therapy. Similar to the results
of supportive therapy alone, the effectiveness of dantrolene
including additive medication was weaker than in dantrolene
as a monotherapy or other kinds of therapy regimens.
As shown in Figure 2, the complete time of remission was sig-
nificantly different between the four treatment groups
(ANOVA, F = 4.02; df = 3; p = 0.008). After adjustment for
multiple testing by the Bonferroni method, the complete time
of remission was significantly shorter in only dantrolene mono-
therapy compared to dantrolene with additive medication (p =
0.012). In a logistic regression with adjustment for age, gen-
der, and severity code, a significant predictor of the medica-
mentous treatment for the complete time of remission
(dichotomized by median) could be found. In ascending order
of elongated time of remission, the following odds ratios (ORs)
were observed: 0.40 (95% confidence interval [CI] 0.20 to
1.19) for dantrolene monotherapy, 0.81 (95% CI 0.40 to 1.66)
for a mainly supportive therapy, 1.06 (95% CI 0.59 to 1.90) for
'other medication,' and 1.56 (95% CI 0.84 to 2.91) for dantro-
lene with additive medication.
Figure 1
Distribution of frequency of neuroleptic malignant syndrome treatment Distribution of frequency of neuroleptic malignant syndrome treatment. Dantrolene mono: dantrolene monotherapy; dantrolene +: dantrolene with 
additive medication (including bromocriptine, amantadine, and electroconvulsive therapy treatment); other medication: any medical therapy (exclud-
ing dantrolene); only supportive: cooling, infusion, and restoring electrolyte balance (no medication).
Table 1
Efficacy of treatment
Effectiveness within 24 hoursa Complete remission in days Mortality
Yes No
Dantrolene monotherapy 23 (76.7%) 7 (23.3%) 9.4 (SD 12.7) 6/37 (16.2%)
Dantrolene with additive medication 30 (44.1%) 38 (55.9%) 19.0 (SD 31.6) 6/82 (7.3%)
Other medication 44 (67.7%) 21 (32.3%) 9.5 (SD 9.8) 9/101 (8.9%)
Only supportive therapy 9 (37.5%) 15 (62.5%) 9.2 (SD 18.4) 1/51 (2.0%)
aMissing values are due to the lack of detailed information in the reports. SD, standard deviation.Critical Care    Vol 11 No 1    Reulbach et al.
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In regard to prior medicamentous treatment in addition to neu-
roleptics, lithium was administered in 30 (11.1%) cases and
antidepressants in 15 (5.5%) cases. Overall, 114 (42.1%)
cases of NMS were caused by neuroleptic monotherapies, 21
(7.7%) cases were caused by atypical neuroleptics, 17 (6.3%)
cases were caused by depot/intramuscular application, and
16 (5.9%) cases were caused otherwise (for example, by with-
drawal of antiparkinsonian agents). The remaining 96 (35.4%)
cases were caused by other combination therapies (seven
cases were described imprecisely in the case reports and
were therefore excluded).
Furthermore, a significant association of prior medication with
the complete time of regression could be observed (ANOVA,
F = 2.76; df = 4; p = 0.029). Depot neuroleptics were found
to have the highest complete time of remission, which was sig-
nificantly longer than after NMS through monotherapy of typi-
cal neuroleptics, even after Bonferroni correction for multiple
testing (p = 0.015).
In regard to the efficacy of dantrolene therapy, the history of
medicamentous treatment prior to NMS was also relevant. If
the premedication was a neuroleptic monotherapy, the com-
plete time of remission was significantly shorter with a dantro-
lene monotherapy (t = -2.97; p  = 0.004), whereas it was
Table 2
Efficacy of treatment
Effectiveness on the basis of 
increase of dosage
Relapse on the basis of 
decrease of dosage
Improvement of symptoms
Fever Rigor Both Not mentioned
Dantrolene monotherapy 2/37 (5.4%) 3/37 (8.1%) 9 (24.3%) 4 (10.8%) 9 (24.3%) 15 (40.5%)
Dantrolene with additive medication 5/82 (6.1%) 7/82 (8.5%) 10 (12.2%) 3 (3.7%) 12 (14.6%) 57 (69.5%)
Other medication 4/101 (4.0%) 17/101 (16.8%) 12 (11.9%) 2 (2.0%) 14 (13.9%) 73 (72.3%)
Only supportive therapy Not applicable Not applicable 1 (2.0%) - 1 (2.0%) 49 (96.1%)
Figure 2
Complete remission in days categorized by treatment expressed through natural logarithm Complete remission in days categorized by treatment expressed through natural logarithm. To calculate the complete remission in days, the natural 
logarithm shown above should be multiplied by the Eularian constant (e). Shaded boxes: the box length is the interquartile range; plus signs: outliers: 
cases with more than 1.5 box lengths from the upper or lower edge of the box. Dantrolene mono: dantrolene monotherapy; dantrolene +: dantrolene 
with additive medication (including bromocriptine, amantadine, and electroconvulsive therapy treatment); other medication: any medical therapy 
(excluding dantrolene); only supportive: cooling, infusion, and restoring electrolyte balance (no medication).Available online http://ccforum.com/content/11/1/R4
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longer (if not significantly elongated) if premedication was
comprised of a combination therapy of neuroleptics.
Discussion
In regard to the efficacy of the dantrolene treatment, in our
analysis the complete time of remission was prolonged by a
combination with dantrolene treatment, and the mortality of a
monotherapy was higher. Furthermore, the time of remission
was not significantly shorter in a dantrolene monotherapy than
in other therapy regimens including only supportive therapy.
This has not been observed before; other studies [11,16,19].
did not examine the efficacy of dantrolene therapy in regard to
monotherapy and therapy with additive medications. In our
study, the additive treatment had the highest OR for an elon-
gated complete regression time whereas the monotherapy
showed the lowest OR. Considering the severity of the NMS
at baseline, patients receiving dantrolene monotherapy were
more severely ill than patients with other medications, which
might explain the high mortality among the group of patients
receiving dantrolene monotherapy.
A possible limitation of the present study is that it is based on
case reports and some case reports were fragmentary in
respect to the information necessary for our purposes. From
the age of patients to dosage specifications, there was a wide
range of missing information. Furthermore, none of the ana-
lyzed case studies addressed a suitable scale for the assess-
ment of rigidity. Also, the temporal sequence of symptoms of
NMS was not described by the latitude of studies.
The short time effectiveness within 24 hours was as effective
in the dantrolene monotherapy group as in the group receiving
different medication and was as ineffective in the dantrolene
treatment group with additive medication as in the group of
patients receiving supportive therapy alone. Nevertheless, in
respect to the effectiveness due to increasing dosages, the
relapse based on the decrease in dosage, or the improvement
of symptoms such as fever and muscle rigidity, no obvious dif-
ferences could be detected in our analysis.
Due to the different severity grades of NMS at baseline, mor-
tality alone, which was examined as a predictor of the benefit
of various medical treatments [19], does not seem to be
sufficient to draw conclusions about the efficacy of each treat-
ment. Therefore, other important variables such as effective-
ness within 24 hours and complete time of remission were
also examined.
Based on the findings of our analysis, dantrolene does not
seem to be the evidence-based treatment of choice in cases
of NMS, which seems to be in accordance with some single-
case reports [2,20]. Nevertheless, there is also no evidence to
explicitly deny a benefit of a dantrolene therapy. In some
cases, dantrolene was very successfully used after some other
vain treatment trials or after a period of time with only support-
ive treatment [21-23]. The latter might also be contradictory to
the argument that time by itself leads to improvement [24].
Further investigations are still needed to discover both the eti-
opathology of NMS and its causal treatment. A promising
approach might be the further exploration of possible central
effects of dantrolene, which is still known as a peripheral mus-
cle relaxant [12,13].
However, due to the low incidence of NMS, large prospective
studies will be difficult to conduct, so further investigations will
likely have to rely on case reports again. The success of such
analyses most likely will depend on the accuracy, uniformity,
and completeness of these reports.
Pharmacological risk factors for the development of NMS
include high neuroleptic dosage, high rate of dose increase,
and parenteral administration [25]. In regard to clinical risk fac-
tors, the available information is limited. It has been suggested
that the recognition of an acute catatonic or disorganized syn-
drome is important in preventing NMS [26].
Conclusion
Independent of treatment options, it is still necessary to dis-
continue potentially contributing medication even before the
diagnosis is definite [27]. Dantrolene might not be the evi-
dence-based treatment of choice in cases of NMS, but it might
be useful if premedication consisted of a neuroleptic
monotherapy.
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